Literature DB >> 21711350

CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Marius Strioga1, Vita Pasukoniene, Dainius Characiejus.   

Abstract

Chronic antigenic stimulation leads to gradual accumulation of late-differentiated, antigen-specific, oligoclonal T cells, particularly within the CD8(+) T-cell compartment. They are characterized by critically shortened telomeres, loss of CD28 and/or gain of CD57 expression and are defined as either CD8(+) CD28(-) or CD8(+) CD57(+) T lymphocytes. There is growing evidence that the CD8(+) CD28(-) (CD8(+) CD57(+)) T-cell population plays a significant role in various diseases or conditions, associated with chronic immune activation such as cancer, chronic intracellular infections, chronic alcoholism, some chronic pulmonary diseases, autoimmune diseases, allogeneic transplantation, as well as has a great influence on age-related changes in the immune system status. CD8(+) CD28(-) (CD8(+) CD57(+)) T-cell population is heterogeneous and composed of various functionally competing (cytotoxic and immunosuppressive) subsets thus the overall effect of CD8(+) CD28(-) (CD8(+) CD57(+)) T-cell-mediated immunity depends on the predominance of a particular subset. Many articles claim that CD8(+) CD28(-) (CD8(+) CD57(+)) T cells have lost their proliferative capacity during process of replicative senescence triggered by repeated antigenic stimulation. However recent data indicate that CD8(+) CD28(-) (CD8(+) CD57(+)) T cells can transiently up-regulate telomerase activity and proliferate under certain stimulation conditions. Similarly, conflicting data is provided regarding CD8(+) CD28(-) (CD8(+) CD57(+)) T-cell sensitivity to apoptosis, finally leading to the conclusion that this T-cell population is also heterogeneous in terms of its apoptotic potential. This review provides a comprehensive approach to the CD8(+) CD28(-) (CD8(+) CD57(+)) T-cell population: we describe in detail its origins, molecular and functional characteristics, subsets, role in various diseases or conditions, associated with persistent antigenic stimulation.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21711350      PMCID: PMC3173691          DOI: 10.1111/j.1365-2567.2011.03470.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  148 in total

1.  From vanilla to 28 flavors: multiple varieties of T regulatory cells.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

2.  CD8(+)CD103(+) regulatory T cells in spontaneous tolerance of liver allografts.

Authors:  Ling Lu; Yue Yu; Guoqiang Li; Liyong Pu; Feng Zhang; Songguo Zheng; Xuehao Wang
Journal:  Int Immunopharmacol       Date:  2009-01-31       Impact factor: 4.932

Review 3.  Central role of ILT3 in the T suppressor cell cascade.

Authors:  Nicole Suciu-Foca; Raffaello Cortesini
Journal:  Cell Immunol       Date:  2007-10-17       Impact factor: 4.868

4.  Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia.

Authors:  D Serrano; J Monteiro; S L Allen; J Kolitz; P Schulman; S M Lichtman; A Buchbinder; V P Vinciguerra; N Chiorazzi; P K Gregersen
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

5.  Dynamics of T cell responses in HIV infection.

Authors:  Victor Appay; Laura Papagno; Celsa A Spina; Pokrath Hansasuta; Abigail King; Louise Jones; Graham S Ogg; Susan Little; Andrew J McMichael; Douglas D Richman; Sarah L Rowland-Jones
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

6.  Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis.

Authors:  N J Borthwick; M Lowdell; M Salmon; A N Akbar
Journal:  Int Immunol       Date:  2000-07       Impact factor: 4.823

Review 7.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

8.  Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.

Authors:  Mihaela Petrova; Maria Muhtarova; Maria Nikolova; Svetoslav Magaev; Hristo Taskov; Diana Nikolovska; Zahariy Krastev
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

9.  Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer.

Authors:  T Okada; T Iiai; Y Kawachi; T Moroda; Y Takii; K Hatakeyama; T Abo
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

10.  Premature aging of T cells is associated with faster HIV-1 disease progression.

Authors:  Weiwei Cao; Beth D Jamieson; Lance E Hultin; Patricia M Hultin; Rita B Effros; Roger Detels
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

View more
  165 in total

1.  Localization of CD8 T cell epitope within cardiac myosin heavy chain-α334-352 that induces autoimmune myocarditis in A/J mice.

Authors:  Chandirasegaran Massilamany; Arunakumar Gangaplara; Rakesh H Basavalingappa; Rajkumar A Rajasekaran; Vahid Khalilzad-Sharghi; Zhongji Han; Shadi Othman; David Steffen; Jay Reddy
Journal:  Int J Cardiol       Date:  2015-09-18       Impact factor: 4.164

2.  Mesenchymal stem cells control alloreactive CD8(+) CD28(-) T cells.

Authors:  A U Engela; C C Baan; N H R Litjens; M Franquesa; M G H Betjes; W Weimar; M J Hoogduijn
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

3.  The expression of molecule CD28 and CD38 on CD4⁺/CD8⁺ T lymphocytes in thymus and spleen elicited by Schistosoma japonicum infection in mice model.

Authors:  Na Li; Peng-yu Ji; Lan-gui Song; Jun-xia Lei; Zhi-yue Lv; Zhong-dao Wu; Xiao Shao; Xi Sun
Journal:  Parasitol Res       Date:  2015-05-24       Impact factor: 2.289

4.  Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis.

Authors:  Gang Li; Adriana T Larregina; Robyn T Domsic; Donna B Stolz; Thomas A Medsger; Robert Lafyatis; Patrizia Fuschiotti
Journal:  J Invest Dermatol       Date:  2016-12-22       Impact factor: 8.551

5.  CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis.

Authors:  Ratanesh Kumar Seth; Suvarthi Das; Ashutosh Kumar; Anindya Chanda; Maria B Kadiiska; Gregory Michelotti; Jose Manautou; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2013-11-07       Impact factor: 4.219

6.  Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.

Authors:  Eleanor M P Wilson; Amrit Singh; Katherine Huppler Hullsiek; Dave Gibson; W Keith Henry; Ken Lichtenstein; Nur F Önen; Erna Kojic; Pragna Patel; John T Brooks; Irini Sereti; Jason V Baker
Journal:  J Infect Dis       Date:  2014-05-09       Impact factor: 5.226

7.  Immunologic Aging in Adults with Congenital Heart Disease: Does Infant Sternotomy Matter?

Authors:  Robert W Elder; Roshan P George; Nancy M McCabe; Fred H Rodriguez; Wendy M Book; William T Mahle; Allan D Kirk
Journal:  Pediatr Cardiol       Date:  2015-04-28       Impact factor: 1.655

8.  New Murine Model of Early Onset Autoimmune Thyroid Disease/Hypothyroidism and Autoimmune Exocrinopathy of the Salivary Gland.

Authors:  Timothy Daniel Kayes; Gary A Weisman; Jean M Camden; Lucas T Woods; Cole Bredehoeft; Edward F Downey; James Cole; Helen Braley-Mullen
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

9.  Altered CD4+ T cell immunity in nurses occupationally exposed to viral pathogens.

Authors:  G Elias; A Souquette; S Heynderickx; I De Meester; H Jansens; P Beutels; P Van Damme; E Smits; P G Thomas; V Van Tendeloo; B Ogunjimi
Journal:  Clin Exp Immunol       Date:  2018-09-19       Impact factor: 4.330

Review 10.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.